Kiromic BioPharma (KRBP) Issues Business Update; Reports Q3 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Kiromic BioPharma Provides Business Update and Reports Third Quarter 2021 Financial Results
March 11, 2022 4:02 PM ESTQuarter Updates Include Companys Progress in the Following Areas:
Expansion of DIAMOND® AI Platform to More than 1.5 Billion Data Points
Completion of InSilico Solutions, LLC Acquisition
Closing of Public Offering
Addition of Key Personnel Across Bioinformatics, Clinical Translational, Manufacturing, and Operations
HOUSTON--(BUSINESS WIRE)-- Kiromic BioPharma, Inc. (NASDAQ: KRBP) (Kiromic or the Company), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND®... More
